- Home
- CLPR vs DTIL Comparison
CLPR vs DTIL Comparison
Compare CLPR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- DTIL
- Stock Information
- Founded
- CLPR 2015
- DTIL 2006
- Country
- CLPR United States
- DTIL United States
- Employees
- CLPR N/A
- DTIL N/A
- Industry
- CLPR Real Estate Investment Trusts
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- DTIL Health Care
- Exchange
- CLPR Nasdaq
- DTIL Nasdaq
- Market Cap
- CLPR 57.8M
- DTIL 51.6M
- IPO Year
- CLPR 2017
- DTIL 2019
- Fundamental
- Price
- CLPR $3.57
- DTIL $4.65
- Analyst Decision
- CLPR
- DTIL Strong Buy
- Analyst Count
- CLPR 0
- DTIL 2
- Target Price
- CLPR N/A
- DTIL $47.00
- AVG Volume (30 Days)
- CLPR 89.5K
- DTIL 534.1K
- Earning Date
- CLPR 07-31-2025
- DTIL 07-31-2025
- Dividend Yield
- CLPR 10.64%
- DTIL N/A
- EPS Growth
- CLPR N/A
- DTIL N/A
- EPS
- CLPR N/A
- DTIL N/A
- Revenue
- CLPR $152,413,000.00
- DTIL $51,141,000.00
- Revenue This Year
- CLPR N/A
- DTIL N/A
- Revenue Next Year
- CLPR N/A
- DTIL $30.20
- P/E Ratio
- CLPR N/A
- DTIL N/A
- Revenue Growth
- CLPR 8.63
- DTIL N/A
- 52 Week Low
- CLPR $3.38
- DTIL $3.61
- 52 Week High
- CLPR $7.12
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- CLPR 39.88
- DTIL 48.09
- Support Level
- CLPR $3.65
- DTIL $4.08
- Resistance Level
- CLPR $3.94
- DTIL $4.60
- Average True Range (ATR)
- CLPR 0.16
- DTIL 0.30
- MACD
- CLPR -0.02
- DTIL 0.01
- Stochastic Oscillator
- CLPR 0.00
- DTIL 54.64
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.